Teva's COPAXONE cleared in Japan for prevention of relapse of MS

• The Japanese Ministry of Health, Labour and Welfare approves Teva Pharmaceutical Industries' (NYSE:TEVA) COPAXONE (glatiramer acetate injection) 20 mg for the prevention of relapse of multiple sclerosis (MS). The product will be commercialized there by Takeda Pharmaceutical (OTCPK:TKPHF) (TKPYY).
• COPAXONE is Teva's biggest seller by far, generating $4.2B in sales over the past four quarters.